DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: SPIRIVA

Summary for Tradename: SPIRIVA

Patents:9
Applicants:1
NDAs:1
Suppliers: see list3
drug
patent expirations by year for
 SPIRIVA

Pharmacology for Tradename: SPIRIVA

Drug ClassAnticholinergic
Mechanism of ActionCholinergic Antagonists

Clinical Trials for: SPIRIVA

Dynamic Hyperinflation and Tiotropium
Status: Completed Condition: COPD

Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea
Status: Completed Condition: Chronic Obstructive Pulmonary Disease

Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers
Status: Completed Condition: Healthy

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS 250/50mcg Plus SPIRIVA HANDIHALER Versus SPIRIVA HANDIHALER Plus Placebo DISKUS in Subjects With Chronic Obstructive Pulmonary Disease (COPD). SPIRIVA and HANDIHALER Are Trade Marks of Boehringer Ingelheim
Status: Completed Condition: Pulmonary Disease, Chronic Obstructive

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed Condition: Chronic Obstructive Pulmonary Disease; Bronchitis; Emphysema

Tiotropium and Salmeterol PK Study in COPD Patients
Status: Completed Condition: Pulmonary Disease, Chronic Obstructive

Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China
Status: Active, not recruiting Condition: Chronic Obstructive Pulmonary Disease

Study to Evaluate the Effects of Tiotropium Bromide on Chronic Obstructive Pulmonary Disease (COPD) During Exercise
Status: Completed Condition: COPD

Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)
Status: Completed Condition: Asthma

Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control
Status: Withdrawn Condition: Chronic Obstructive Pulmonary Disease (COPD)

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
SPIRIVA
tiotropium bromide monohydrate
POWDER;INHALATION021395Jan 30, 2004RXYes6,777,423<disabled>YY<disabled>
Boehringer Ingelheim
SPIRIVA
tiotropium bromide monohydrate
POWDER;INHALATION021395Jan 30, 2004RXYes6,908,928<disabled>YY<disabled>
Boehringer Ingelheim
SPIRIVA
tiotropium bromide monohydrate
POWDER;INHALATION021395Jan 30, 2004RXYes7,070,800<disabled>Y<disabled>
Boehringer Ingelheim
SPIRIVA
tiotropium bromide monohydrate
POWDER;INHALATION021395Jan 30, 2004RXYes7,309,707<disabled>YY<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc